Skip to main content
SpringerLink
Log in

Onkologische Embolisation

  • Chapter
  • First Online:
Angiofibel

  • 2640 Accesses

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) ist weltweit betrachtet das fünfthäufigste Malignom bei steigender Inzidenz. In mehr als 80 % der Fälle ist es die Folge einer Leberzirrhose und inzwischen die Haupttodesursache bei Patienten mit dieser Erkrankung in Europa. Im Gegensatz zum HCC verfügt das umgebende nichttumoröse Lebergewebe zusätzlich über die portalvenöse Blutzufuhr. Aufgrund dessen können bei der transarteriellen Chemoembolisation (TACE) tumorversorgende arterielle Gefäße selektiv verschlossen werden, ohne einen Infarkt des umgebenden, gesunden, auch über die Pfortader perfundierten Lebergewebes zu induzieren. Ein weiterer wichtiger Vorteil der TACE gegenüber der systemischen Chemotherapie ist die Tatsache, dass die Positionierung des Mikrokatheters unmittelbar vor die tumorversorgenden Gefäße, eine deutlich höhere Zytostatikakonzentration in der Leber im Vergleich zur systemischen Applikation ermöglicht. Dadurch wird das gesunde Leberparenchym geschont und die systemische Toxizität deutlich reduziert.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  1. Abbott AM, Doepker MP, Kim Y, Perez MC, Gandle C, Thomas KL, Choi J, Shridhar R, Zager JS (2017) Hepatic progression-free and overall survival after regional therapy to the liver for metastatic melanoma. Am J Clin Oncol. [PMID: 28059929]. https://doi.org/10.1097/COC0000000000000356

  2. Akinwande O, Scoggins C, Martin RCG (2016) Early experience with 70–150 μm irinotecan drug-eluting beads (M1-DEBIRI) fort he treatment of unresectable hepatic colorectal metastases. Anticancer Res 36:3413–3418

    Google Scholar 

  3. Albert M, Kiefer MV, Sun W et al (2011) Chemoembolization of colorectal liver metastases with cisplatin, doxorubicin, mitomycin C, ethiodol and polyvinyl alcohol. Cancer 117:343–352

    CAS  PubMed  Google Scholar 

  4. Alexander HR Jr, Butler CC (2010) Development of isolated hepatic perfusion via the operative and percutaneous techniques for Patients with isolated and unresectable liver metastases. Cancer J 16(2):132–141. [PMID: 20404610]. https://doi.org/10.1097/PPO.0b013e3181db9c0a

    Article  PubMed  Google Scholar 

  5. Alexander HR Jr, Bartlett DL, Libutti SK, Pingpank JF, Fraker DL, Royal R, Steinberg SM, Helsabeck CB, Beresneva TH (2009) Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol 16(7):1852–1859. [PMID: 19434456]. https://doi.org/10.1245/s10434-009-0482-9

    Article  PubMed  Google Scholar 

  6. Aliberti C, Benea G, Tilli M et al (2008) Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release Doxorubicin-eluting beads: preliminary results. Cradiovasc Interv Radiol 31:883–888

    Google Scholar 

  7. Allen PJ, Nissan A, Picon AI, Kemeny N, Dudrick P, Ben-Porat L et al (2005) Technical complications and durability of hepatic artery infusion pumps for unresectable colorectal liver metastases: an institutional experience of 544 consecutive cases. J Am Coll Surg 201(1):57–65. Epub 2005/06/28

    Google Scholar 

  8. Arai H, Abe T, Takayama H, Toyoda M, Ueno T, Kakizaki S et al (2015) Safety and efficacy of balloon-occluded transcatheter arterial chemoembolization using miriplatin for hepatocellular carcinoma. Hepatol Res 45(6):663–666

    CAS  PubMed  Google Scholar 

  9. Ausman RK (1961) Development of a technic for isolated perfusion of the liver. N Y State J Med 61:3993–3997. [PMID: 13863315]

    CAS  PubMed  Google Scholar 

  10. Bartlett DL, Libutti SK, Figg WD, Fraker DL, Alexander HR (2001) Isolated hepatic perfusion for unresectable hepatic metastases from colorectal cancer. Surgery 129(2):176–187. [PMID: 11174711]. https://doi.org/10.1067/msy.2001.110365

    Article  CAS  PubMed  Google Scholar 

  11. Bedikian AY, Legha SS, Mavligit G et al (1995) Treatment of uveal melanoma metastatic to the liver. Cancer 76:1665–1670

    CAS  PubMed  Google Scholar 

  12. Bhagat N et al (2013) Phase II study of chemoembolization with drug-eluting beads in Patients with hepatic neuroendocrine metastases: high incidence of biliary injury. Cardiovasc Interv Radiol 36(2):449–459

    Google Scholar 

  13. Bilbao JI, Reiser MF (2008) Liver radioembolization with 90Y microspheres. 90Y microspheres: concepts and principles. Springer Verlag, Berlin/Heidelberg/New York, S S7

    Google Scholar 

  14. Bloomston M et al (2007) Hepatic artery chemoembolization in 122 patients with metastatic carcinoid tumor: lessons learned. J Gastrointest Surg 11(3):264–271

    Google Scholar 

  15. Boehm LM, Jayakrishnan TT, Miura JT et al (2015) Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol 111:213–220

    PubMed  Google Scholar 

  16. Boige V, Malka D, Elias D et al (2007) Hepatic arterial infusion of Oxaliplatin and intravenous LV5FU2 in unresectable liver metastases from colorectal cancer after systemic chemotherapy failure. Ann Surg Oncol 15:219–226

    PubMed  Google Scholar 

  17. Bonomo G, Pedicini V, Monfardini L, Della Vigna P, Poretti D, Orgera G et al (2010) Bland embolization in Patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Interv Radiol 33(3):552–559. Epub 2009/12/04

    Google Scholar 

  18. Breedis C, Young G (1954a) The blood supply at neoplasm of the liver. Am J Pathol 30:969–985

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Breedis C, Young G (1954b) The blood supply of neoplasms in the liver. Am J Pathol 30(5):969–977 [PMID: 13197542 PMCID: PMC1942491]

    Google Scholar 

  20. Brown DB, Pilgram TK, Darcy MD, Fundakowski CE, Lisker-Melman M, Chapman WC et al (2005) Hepatic arterial chemoembolization for hepatocellular carcinoma: comparison of survival rates with different embolic agents. J Vasc Interv Radiol 16(12):1661–1666

    PubMed  Google Scholar 

  21. Buijs M, Kamel IR, Vossen JA et al (2007) Assessment of metastatic breast cancer response to chemoembolization with contrast agent-enhanced and diffusion-weighted MR imaging. J Vasc Interv Radiol 18:957–963

    PubMed  Google Scholar 

  22. Burger I, Hong K, Schulick R et al (2005) Transcatheter arterial chemoembolization in unresectable cholangiocarcinoma: initial experience in a single institution. J Vasc Interv Radiol 16:353–361

    PubMed  Google Scholar 

  23. Calender A (2000) Molecular genetics of neuroendocrine tumors. Digestion 62(Suppl 1):3–18

    CAS  PubMed  Google Scholar 

  24. Cao CQ et al (2010) Radioembolization with yttrium microspheres for neuroendocrine tumour liver metastases. Br J Surg 97(4):537–543

    CAS  PubMed  Google Scholar 

  25. Carrasco CH et al (1986) The carcinoid syndrome: palliation by hepatic artery embolization. AJR Am J Roentgenol 147(1):149–154

    CAS  PubMed  Google Scholar 

  26. Chan AO, Yuen MF, Hui CK, Tso WK, Lai CL (2002) A prospective study regarding the complications of transcatheter intraarterial lipiodol chemoembolization in Patients with hepatocellular carcinoma. Cancer 94(6):1747–1752

    PubMed  Google Scholar 

  27. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinomA. A randomized controlled study. Cancer 74(9):2449–2453. Epub 1994/11/01

    CAS  PubMed  Google Scholar 

  28. Chung JW et al (1996) Hepatic tumors: predisposing factors for complications of transcatheter oily chemoembolization. Radiology 198(1):33–40

    CAS  PubMed  Google Scholar 

  29. Collins JM (1984) Pharmacologic rationale for regional drug delivery. J Clin Oncol 2:498–504

    CAS  PubMed  Google Scholar 

  30. Covey AM, Brody LA, Maluccio MA, Getrajdman GI, Brown KT Covey A et al (2002) Variant hepatic arterial anatomy revisited: digital subtraction angiography performed in 600 Patients. Radiology 224:542–547

    Google Scholar 

  31. De Baere T et al (2008) Transarterial chemoembolization of liver metastases from well differentiated gastroenteropancreatic endocrine tumors with doxorubicin-eluting beads: preliminary results. J Vasc Interv Radiol 19(6):855–861

    PubMed  Google Scholar 

  32. De Baere T et al (2015) GEP-NETS update: interventional radiology: role in the treatment of liver metastases from GEP-NETs. Eur J Endocrinol 172(4):R151–R166

    PubMed  Google Scholar 

  33. De Baere T, Arai Y, Lencioni R et al (2016) Treatment of liver tumors with Lipiodol TACE: technical recommendations from experts opinion. Cardiovasc Interv Radiol 39:334–343

    Google Scholar 

  34. De Vries MR, Borel Rinkes IH, van de Velde CJ, Wiggers T, Tollenaar RA, Kuppen PJ, Vahrmeijer AL, Eggermont AM (1998) Isolated hepatic perfusion with tumor necrosis factor alpha and melphalan: experimental studies in pigs and phase I data from humans. Recent Results Cancer Res 147:107–119. [PMID: 9670273]

    PubMed  Google Scholar 

  35. Demachi H et al (1995) The protective effect of portoarterial shunts after experimental hepatic artery embolization in rats with liver cirrhosis. Cardiovasc Interv Radiol 18(2):97–101

    CAS  Google Scholar 

  36. Deneve JL, Choi J, Gonzalez RJ, Conley AP, Stewart S, Han D, Werner P, Chaudhry TA, Zager JS (2012) Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma. Cardiovasc Interv Radiol 35(6):1480–1487. [PMID: 22699779]. https://doi.org/10.1007/s00270-012-0425-x

    Article  Google Scholar 

  37. Dong XD, Carr BI (2011) Hepatic artery chemoembolization for the treatment of liver metastases from neuroendocrine tumors: a long-term follow-up in 123 patients. Med Oncol 28(Suppl 1):S286–S290

    Google Scholar 

  38. Duran R, Sharma K, Dreher MR et al (2016) A novel inherently radiopaque bead for transarterial embolization to treat liver cancer – a preclinical study. Theranostics 6:28–39

    Google Scholar 

  39. Dycker de RP, Timmermann J (1991) Combined intraarterial hepatic infusion of degradable starch microspheres and cytostatics in the treatment of breast cancer liver metastases. Reg Cancer Treat 3:302–304

    Google Scholar 

  40. EASL-EORTC clinical practice guidelines (2012) Management of hepatocellular carcinoma. J Hepatol 56(4):908–943. Epub 2012/03/20

    Google Scholar 

  41. Eichler K, Jakobi S, Gruber-Rouh T et al (2013) Transarterial chemoembolization (TACE) with gemcitabine: phase II study in patients with liver metastases of breast cancer. Eur J Radiol 82:16–22

    Google Scholar 

  42. Ensminger WD (2002) Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 29:119–125

    CAS  PubMed  Google Scholar 

  43. Eriksson BK et al (1998) Liver embolizations of Patients with malignant neuroendocrine gastrointestinal tumors. Cancer 83(11):2293–2301

    CAS  PubMed  Google Scholar 

  44. Erinjeri JP, Salhab HM, Covey AM, Getrajdman GI, Brown KT (2010) Arterial patency after repeated hepatic artery bland particle embolization. J Vasc Interv Radiol 21(4):522–526. Epub 2010/03/02

    PubMed  PubMed Central  Google Scholar 

  45. Fiore F et al (2014) Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors. Endocrine 47(1):177–182

    CAS  PubMed  Google Scholar 

  46. Fiorentini G, Aliberti C, Turrisi G et al (2007) Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a phase II clinical study. In vivo 21:1085–1092

    CAS  PubMed  Google Scholar 

  47. Fiorentini G, Aliberti C, Del Conte A et al (2009) Intra-arterial hepatic chemoembolization (TACE) of liver metastases from ocular melanoma with slow-release irinotecan-eluting beads. Early results of a phase II clinical study. In vivo 23:131–138

    PubMed  Google Scholar 

  48. Forster MR, Rashid OM, Perez MC, Choi J, Chaudhry T, Zager JS (2014) Chemosaturation with percutaneous hepatic perfusion for unresectable metastatic melanoma or sarcoma to the liver: a single institution experience. J Surg Oncol 109(5):434–439. [PMID: 24249545 PMCID: PMC4503311]. https://doi.org/10.1002/jso.23501

    Article  PubMed  Google Scholar 

  49. Frilling A et al (2014) Recommendations for management of Patients with neuroendocrine liver metastases. Lancet Oncol 15(1):e8–e21

    PubMed  Google Scholar 

  50. Gaur SK et al (2011) Hepatic arterial chemoembolization using drug-eluting beads in gastrointestinal neuroendocrine tumor metastatic to the liver. Cardiovasc Interv Radiol 34(3):566–572

    Google Scholar 

  51. Geschwind JFH, Ramsey DE, Cleffken B, van der Wal BCH, Kobeiter H, Juluru K et al (1992) Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Interv Radiol 26(2):111–117

    Google Scholar 

  52. Giannelli G, Pierri F, Trerotoli P, Marinosci F, Serio G, Schiraldi O et al (2002) Occurrence of portal vein tumor thrombus in hepatocellular carcinoma affects prognosis and survival. A retrospective clinical study of 150 cases. Hepatol Res 24(1):50. Epub 2002/09/24

    PubMed  Google Scholar 

  53. Giroux M-F, Baum RA, Soulen MC (2004) Chemoembolization of liver metastasis from breast carcinoma. J Vasc Interv Radiol 15:289–291

    PubMed  Google Scholar 

  54. Giunchedi P, Maestri M, Gavini E et al (2013) Transarterial chemoembolization (TACE) of hepatocellular carcinoma (HCC). Agents and drugs: an overview. Part 2. Expert Opin Drug Deliv 10:799–810

    CAS  PubMed  Google Scholar 

  55. Gruber-Rouh T, Naguib NN, Eichler K et al (2014) Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: long-term results over a 10-year period. Int J Cancer 134:1225–1231

    CAS  PubMed  Google Scholar 

  56. Guiu B et al (2012) Liver/biliary injuries following chemoembolisation of endocrine tumours and hepatocellular carcinoma: lipiodol vs. drug-eluting beads. J Hepatol 56(3):609–617

    CAS  PubMed  Google Scholar 

  57. Gupta S (2013) Intra-arterial liver-directed therapies for neuroendocrine hepatic metastases. Semin Interv Radiol 30(1):28–38

    Google Scholar 

  58. Gupta S, Yao JC, Ahar K et al (2003) Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J 9:261–267

    PubMed  Google Scholar 

  59. Gupta S et al (2005) Hepatic arterial embolization and chemoembolization for the treatment of Patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8):1590–1602

    PubMed  Google Scholar 

  60. Gusani NJ, Balaa FK, Steel JL et al (2008) Treatment of unresectable cholangiocarcinoma with Gemcitabine-based transcatheter arterial chemoembolization (TACE): a single-institution experience. J Gastrointest Surg 12:129–137

    PubMed  Google Scholar 

  61. Halappa VG, Bonekamp S, Corona-Villalobos CP et al (2012) Intrahepatic cholangiocarcinoma treated with local-regional therapy: quantitative volumetric apparent diffusion coefficient maps for assessment of tumor response. Radiology 264:285–294

    PubMed  Google Scholar 

  62. Hamada A, Yamakado K, Nakatsuka A, Takaki H, Akeboshi M, Takeda K (2004) Hepatic arterial infusion chemotherapy with use of an implanted port system in Patients with advanced hepatocellular carcinoma: prognostic factors. J Vasc Interv Radiol 15(8):835–841. Epub 2004/08/07

    PubMed  Google Scholar 

  63. Hamaguchi S, Lohman BD, Ogawa Y, Arai Y, Hashimoto K, Matsumoto J et al (2015) Preliminary findings of arterial embolization with balloon-occluded and flow-dependent histoacryl glue embolization in a swine model. Jpn J Radiol 33(6):344–351

    PubMed  Google Scholar 

  64. Hatanaka Y, Yamashita Y, Takahashi M, Koga Y, Saito R, Nakashima K et al (1995) Unresectable hepatocellular-carcinoma – analysis of prognostic factors in transcatheter management. Radiology 195(3):747–752

    Google Scholar 

  65. Herber S, Otto G, Schneider J et al (2007) Transarterial chemoembolization (TACE) for inoperable intrahepatic cholangiocarcinoma. Cardiovasc Interv Radiol 30:1156–1165

    CAS  Google Scholar 

  66. Hickson G (2015) Single centre experience of chemosaturation percutaneous hepatic perfusion in the treatment of metastaticuveal melanoma. J Clin Oncol 33(15_suppl):e20000-e

    Google Scholar 

  67. Hofmann H, von Haken R, Werner J, Kortes N, Bergmann F, Schemmer P, Jager D, Radeleff B, Schulze-Bergkamen H (2014) Unresectable isolated hepatic metastases from solid pseudopapillary neoplasm of the pancreas: a case report of chemosaturation with high-dose melphalan. Pancreatology 14(6):546–549. [PMID: 25280592]. https://doi.org/10.1016/j.pan.2014.08.006

    Article  PubMed  Google Scholar 

  68. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF (2006a) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12(8):2563–2567. Epub 2006/04/28

    CAS  PubMed  Google Scholar 

  69. Hong K, Khwaja A, Liapi E, Torbenson MS, Georgiades CS, Geschwind JF (2006b) New intra-arterial drug delivery system for the treatment of liver cancer: preclinical assessment in a rabbit model of liver cancer. Clin Cancer Res 12(8):2563–2567. Epub 2006/04/28

    CAS  PubMed  Google Scholar 

  70. Horiguchi Y, Itoh M, Takagawa H, Imai H, Kamei A, Sekoguchi B et al (1992) Assessment of chemoembolization therapy for primary liver-cancer using a stabilized adriamycin-lipiodol suspension. Cancer Chemother Pharmacol 31:S60–S64

    PubMed  Google Scholar 

  71. Hsieh PM, Hung KC, Chen YS (2009) Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review. World J Gastroenterol: WJG 15(37):4726–4788

    CAS  PubMed  Google Scholar 

  72. Hucke F, Sieghart W, Pinter M, Graziadei I, Vogel W, Muller C et al (2014) The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. J Hepatol 60(1):118–126

    PubMed  Google Scholar 

  73. Hughes MS, Zager J, Faries M, Alexander HR, Royal RE, Wood B, Choi J, McCluskey K, Whitman E, Agarwala S, Siskin G, Nutting C, Toomey MA, Webb C, Beresnev T, Pingpank JF (2016) Results of a randomized controlled multicenter phase III trial of percutaneous hepatic perfusion compared with best available care for patients with melanoma liver metastases. Ann Surg Oncol 23(4):1309–1319. [PMID: 26597368]. https://doi.org/10.1245/s10434-015-4968-3

    Article  PubMed  Google Scholar 

  74. Huppert P, Fierlbeck G, Pereira P et al (2010) Transarterial chemoembolization of liver metastases in patients with uveal melanoma. Eur J Radiol 74:e38–e44

    CAS  PubMed  Google Scholar 

  75. Huppert P, Wenzel T, Wietholtz H (2014) Transcatheter arterial chemoembolization (TACE) of colorectal cancer liver metastases by irinotecan-eluting microspheres in a salvage Patient population. Cardiovasc Interv Radiol 37:154–164

    Google Scholar 

  76. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J et al (2005) Enhancement of focal liver lesions at gadoxetic acid-enhanced MR imaging: correlation with histopathologic findings and spiral CT – initial observations. Radiology 234(2):468–478. Epub 2004/12/14

    Google Scholar 

  77. Hur H et al (2009) Comparative study of resection and radiofrequency ablation in the treatment of solitary colorectal liver metastases. Am J Surg 197(6):728–736

    PubMed  Google Scholar 

  78. Hur S et al (2014) Survival outcomes and prognostic factors of transcatheter arterial chemoembolization for hepatic neuroendocrine metastases. J Vasc Interv Radiol 24(7):947–956; quiz 957

    Google Scholar 

  79. Id e JM, Guiu B (2013) Use of Lipiodol as a drug-delivery system for transcatheter arterial chemoembolization of hepatocellular carcinoma: a review. Crit Review Oncol/Hematol 88:530–549

    Google Scholar 

  80. Iezzi R, Marsico VA, Guerra A et al (2015) Trans-arterial chemoembolization with irinotecan-loaded drug-eluting beads (DEBIRI) and capecitabine in refractory liver prevalent colorectal metastases: a phase II single-center study. Cardiovasc Interv Radiol 38:1523–1531

    Google Scholar 

  81. Iñarrairaegui M, Martinez-Cuesta A, Rodríguez M, Bilbao JI, Arbizu J, Benito A, Alegre F, D'Avola D, Herrero JI, Quiroga J, Prieto J, Sangro B et al (2010) Analysis of prognostic factors after yttrium-90 radioembolization of advanced hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 77:1441–1448

    PubMed  Google Scholar 

  82. Ji SK, Cho YK, Ahn YS, Kim MY, Park YO, Kim JK et al (2008) Multivariate analysis of the predictors of survival for Patients with hepatocellular carcinoma undergoing transarterial chemoembolization: focusing on superselective chemoembolization. Korean J Radiol 9(6):534–540. Epub 2008/11/29

    PubMed  PubMed Central  Google Scholar 

  83. Johnson PJ, Kalayci C, Dobbs N, Raby N, Metivier EM, Summers L et al (1991) Pharmacokinetics and toxicity of intraarterial adriamycin for hepatocellular-carcinoma – effect of coadministration of lipiodol. J Hepatol 13(1):120–127

    Google Scholar 

  84. Joskin J et al (2015) Predisposing factors of liver necrosis after transcatheter arterial chemoembolization in liver metastases from neuroendocrine tumor. Cardiovasc Interv Radiol 38(2):372–380

    Google Scholar 

  85. Kadalayil L, Benini R, Pallan L, O'Beirne J, Marelli L, Yu D et al (2013) A simple prognostic scoring system for patients receiving transarterial embolisation for hepatocellular cancer. Ann Oncol 24(10):2565–2570

    CAS  PubMed  PubMed Central  Google Scholar 

  86. Kaltsas GA, Besser GM, Grossman AB (2004) The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 25(3):458–511

    CAS  PubMed  Google Scholar 

  87. Kamat PP et al (2008) Hepatic arterial embolization and chemoembolization in the management of Patients with large-volume liver metastases. Cardiovasc Interv Radiol 31(2):299–307

    Google Scholar 

  88. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J et al (1992) Prospective and randomized clinical-trial for the treatment of hepatocellular-carcinoma – a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (1st cooperative study). Cancer Chemother Pharmacol 31:S1–S6

    Google Scholar 

  89. Kennedy A et al (2007) Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 68(1):13–23

    PubMed  Google Scholar 

  90. Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R, Kennedy A et al (2008a) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 Patients. Am J Clin Oncol 31:271–279

    Google Scholar 

  91. Kennedy AS et al (2008b) Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients. Am J Clin Oncol 31(3):271–279

    PubMed  Google Scholar 

  92. Kerr DJ, Los G (1993) Pharmacokinetik principles of locoregional chemotherapy. Cancer Surv 17:105–122

    Google Scholar 

  93. Kettenbach J, Stadler A, Katzler IV, Schernthaner R, Blum M, Lammer J et al (2008) Drug-loaded microspheres for the treatment of liver cancer: review of current results. Cardiovasc Interv Radiol 31(3):468–476. Epub 2008/01/30

    Google Scholar 

  94. Khoja L, Atenafu EG, Leyvraz S et al (2016) Meta-analysis of phase II trials in metastatic uveal melanoma to determine progression-free and overall survival benchmarks for future phase II trials: an international rare cancers initiative (IRCI)-ocular melanoma initiative ASCO. J Clin Oncol 34(15):9567–9567

    Google Scholar 

  95. Kianmanesh R et al (2010) ENETS consensus guidelines for the management of peritoneal carcinomatosis from neuroendocrine tumors. Neuroendocrinology 91(4):333–340

    CAS  PubMed  Google Scholar 

  96. Kiefer MV, Albert M, McNally M et al (2011) Chemoembolization of intrahepatic cholangiocarcinoma with cisplatinum, doxorubicin, mitomycin C, ethiodol, and polyvenyl alcohol: a 2-center study. Cancer 117:1498–1505

    CAS  PubMed  Google Scholar 

  97. Kim HC, Chung JW, Lee W, Jae HJ, Park JH (2005) Recognizing extrahepatic collateral vessels that supply hepatocellular carcinoma to avoid complications of transcatheter arterial chemoembolization. Radiografics 25(Suppl 1):S25–S39. Epub 2005/10/18

    Google Scholar 

  98. Kim H-C, Chung JW, Choi SH et al (2007) Internal mammary arteries supplying hepatocellular carcinoma: vascular anatomy at digital subtraction angiography in 97 patients. Radiology 242:925–932

    Google Scholar 

  99. Kim JH, Yoon HK, Sung KB et al (2008) Transcatheter arterial chemoembolization or chemoinfusion for unresectable intrahepatic cholangiocarcinoma. Cancer 113:1614–1622

    PubMed  Google Scholar 

  100. Kim KW, Lee JM, Choi BI (2011) Assessment of the treatment response of HCC. Abdom Imaging 36(3):300–314

    PubMed  Google Scholar 

  101. Kim YH et al (1999) Selective hepatic arterial chemoembolization for liver metastases in Patients with carcinoid tumor or islet cell carcinoma. Cancer Investig 17(7):474–478

    CAS  Google Scholar 

  102. Kirchhoff T, Zender L, Merkesdal S et al (2005) Inital experience from a combination of systemic and regional chemotherapy in the treatment of patients with nonresectable cholangiocellular carcinoma in the liver. World J Gastroenterol 11:1091–1095

    PubMed  PubMed Central  Google Scholar 

  103. Kirchhoff TD, Bleck JS, Dettmer A, Chavan A, Rosenthal H, Merkesdal S et al (2007) Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival. Hepatobiliary Pancreat Dis Int 6(3):259–266. Epub 2007/06/06

    CAS  PubMed  Google Scholar 

  104. Klimstra DS (2013) Pathology reporting of neuroendocrine tumors: essential elements for accurate diagnosis, classification, and staging. Semin Oncol 40(1):23–36

    PubMed  Google Scholar 

  105. Kobayashi N, Ishii M, Ueno Y, Kisara N, Chida N, Iwasaki T et al (1999) Co-expression of Bcl-2 protein and vascular endothelial growth factor in hepatocellular carcinomas treated by chemoembolization. Liver 19(1):25–31. Epub 1999/02/03

    CAS  PubMed  Google Scholar 

  106. Konno T, Maeda H, Yokoyama et al (1982) Use of a lipid lymphografic agent Lipiodol as a carrier of high molecular weight antitumor agent SMANCS for hepatocellular carcinoma. Gan To Kagaku Ryoho 9:2005–2015

    Google Scholar 

  107. Kos-Kudla B et al (2010) ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors. Neuroendocrinology 91(4):341–350

    CAS  PubMed  Google Scholar 

  108. Kress O, Wagner H-J, Wied M et al (2003) Transarterial chemoembolization of advanced liver metastases of neuroendocrine tumors – a retrospective single-center analysis. Digestion 68:94–101

    Google Scholar 

  109. Kuhlmann JB, Euringer W, Spangenberg HC et al (2012) Treatment of unresectable cholangiocarcinoma: conventional transarterial chemoembolization compared with drug eluting bead-transarterial chemoembolization and systemic chemotherapy. Eur J Gastroenterol Hepatol 24:437–443

    CAS  PubMed  Google Scholar 

  110. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, Sato KT, Benson A 3rd, Nemcek AA Jr, Gates VL, Abecassis M, Omary RA, Salem R, Kulik LM et al (2008) Safety and efficacy of 90Y radiotherapy for hepatiocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71–81

    PubMed  Google Scholar 

  111. La Rosa S et al (2009) Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 40(1):30–40

    PubMed  Google Scholar 

  112. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A et al (2010) Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Interv Radiol 33(1):41–52. Epub 2009/11/13

    Google Scholar 

  113. Laurent A et al (2004) Location of vessel occlusion of calibrated tris-acryl gelatin microspheres for tumor and arteriovenous malformation embolization. J Vasc Interv Radiol 15(5):491–496

    PubMed  Google Scholar 

  114. Lawrence B et al (2011) The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin N Am 40(1):1–18, vii

    Google Scholar 

  115. Lee KH et al (2008) Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: evaluation with MR imaging and implication for therapy. J Vasc Interv Radiol 19(10):1490–1496

    PubMed  PubMed Central  Google Scholar 

  116. Lerose R, Molinari R, Rocchi E, Manenti F, Villa E (2001) Prognostic features and survival of hepatocellular carcinoma in Italy: impact of stage of disease. Eur J Cancer 37(2):239–245. Epub 2001/02/13

    CAS  PubMed  Google Scholar 

  117. Leyvraz S, Spataro V, Bauer J et al (1997) Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 15:2589–2595

    CAS  PubMed  Google Scholar 

  118. Lim TY, Cheong JY, Cho SW, Sim SJ, Kim JS, Choi SJ et al (2006) Effect of low dose 5-fluorouracil and cisplatin intra-arterial infusion chemotherapy in advanced hepatocellular carcinoma with decompensated cirrhosis. Korean J Hepatol 12(1):65–73. Epub 2006/03/28

    PubMed  Google Scholar 

  119. Liu DM, Salem R, Bui JT, Courtney A, Barakat O, Sergie Z, Atassi B, Barrett K, Gowland P, Oman B, Lewandowski RJ, Gates VL, Thurston KG, Wong CY et al (2005) Angiografic considerations in Patients undergoing liver-directed therapy. J Vasc Interv Radiol 16:911–935

    PubMed  Google Scholar 

  120. Llovet JM, Bruix J (2003) Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37(2):429–442. Epub 2003/01/24

    CAS  PubMed  Google Scholar 

  121. Llovet JM, Bruix J (2008) Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48(Suppl 1):S20–S37. Epub 2008/02/29

    CAS  PubMed  Google Scholar 

  122. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in Patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359(9319):1734–1739. Epub 2002/06/07

    Google Scholar 

  123. Llovet JM, Di Bisceglie AM, Bruix J et al (2008) Design and Endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 100:698–711

    PubMed  Google Scholar 

  124. Loewe C, Schindl M, Cejna M et al (2003) Permanent transarterial embolization of neuroendocrine metastases oft he liver using cyanoacrylate and lipiodol: assessment of mid- and long-term results. Am J Roentgenol 180:1379–1384

    Google Scholar 

  125. Lubienski A, Simon M, Lubienski K, Gellissen J, Hoffmann RT, Jakobs TF et al (2007) Update on chemoinfusion and chemoembolization treatments. Der Radiologe 47(12):1097–1106, 1108. Epub 2007/11/10

    Google Scholar 

  126. Maeda N, Osuga K, Higashihara H et al (2010) In vitro characterization of Cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization. J Vasc Interv Radiol 21:877–881

    PubMed  Google Scholar 

  127. Mahnken AH (2016) Current status of transarterial radioembolization. World J Radiol 8(5):449–459

    PubMed  PubMed Central  Google Scholar 

  128. Makuuchi M et al (1985) Bile duct necrosis: complication of transcatheter hepatic arterial embolization. Radiology 156(2):331–334

    CAS  PubMed  Google Scholar 

  129. Malagari K, Pomoni M, Kelekis A, Pomoni A, Dourakis S, Spyridopoulos T et al (2010) Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinomA. Cardiovasc Interv Radiol 33(3):541–551. Epub 2009/11/26

    Google Scholar 

  130. Malagari K, Kiakidis T, Pomoni M, Moschouris H, Emmanouil E, Spiridopoulos T et al (2016) Pharmacokinetics, safety, and efficacy of chemoembolization with doxorubicin-loaded tightly calibrated small microspheres in patients with hepatocellular carcinomA. Cardiovasc Interv Radiol 39(10):1379–1391

    Google Scholar 

  131. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N et al (2007) Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Interv Radiol 30(1):6–25. Epub 2006/11/15

    Google Scholar 

  132. Marinelli A, de Brauw LM, Beerman H, Keizer HJ, van Bockel JH, Tjaden UR, van de Velde CJ (1996) Isolated liver perfusion with mitomycin C in the treatment of colorectal cancer metastases confined to the liver. Jpn J Clin Oncol 26(5):341–350. [PMID: 8895675]

    CAS  PubMed  Google Scholar 

  133. Marrache F et al (2007) Arterial phase enhancement and body mass index are predictors of response to chemoembolisation for liver metastases of endocrine tumours. Br J Cancer 96(1):49–55

    CAS  PubMed  Google Scholar 

  134. Martin RCG, Robbins K, Tomalty D et al (2009) Transarterial chemoembolization (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J Surg Oncol 7:80–92

    PubMed  PubMed Central  Google Scholar 

  135. Martin RCG, Robbins K et al (2012) Optimal outcomes for liver-dominant metastatic breast cancer with transarterial chemoembolization with drug-eluting beads loaded with doxorubicin. Breast Cancer Res Treat 132:753–763

    CAS  PubMed  Google Scholar 

  136. Matsumoto T, Endo J, Hashida K, Mizukami H, Nagata J, Ichikawa H et al (2016) Balloon-occluded arterial stump pressure before balloon-occluded transarterial chemoembolization. Minim Invasive Ther Allied Technol 25(1):22–28

    PubMed  Google Scholar 

  137. Matsuo N, Uchida H, Sakaguchi H, Nishimine K, Nishimura Y, Hirohashi S et al (1997) Optimal lipiodol volume in transcatheter arterial chemoembolotherapy for hepatocellular carcinoma: study based on Lipiodol accumulation patterns and histopathologic findings. Semin Oncol 24(2):61–70

    Google Scholar 

  138. Mavligit GM, Charnsangavej C, Carrasco H et al (1988) Regression of ocular melanoma metastatic to the liver after hepatic arterial chemoembolization with cisplatin and polyvinyl sponge. JAMA 260:974–976

    CAS  PubMed  Google Scholar 

  139. McCall CM (2012) Ki-67 Proliferation index and mitotic rate discordance in pancreatic neuroendocrine tumors correlates with aggressive histologic features and decreased overall survival. Mod Pathol 25:446A–447A

    Google Scholar 

  140. McDermott EW, Guduric B, Brennan MF (1994) Prognostic variables in Patients with gastrointestinal carcinoid tumours. Br J Surg 81(7):1007–1009

    CAS  PubMed  Google Scholar 

  141. Memon K, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Sato KT, Gupta R, Nikolaidis P, Miller FH, Yaghmai V, Gates VL, Atassi B, Newman S, Omary RA, Benson AB 3rd, Salem R (2012a) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83:887–894

    Google Scholar 

  142. Memon K et al (2012b) Radioembolization for neuroendocrine liver metastases: safety, imaging, and long-term outcomes. Int J Radiat Oncol Biol Phys 83(3):887–894

    PubMed  Google Scholar 

  143. Merkel C (2014) Functional anatomy of liver circulation. Functional molecular imaging in hepatology. Sara Montagnese and Piero Amodio. Bentham Science Publishers, EBSCO Information Services GmbH, Berlin, S 3–13 (11). DOI: 10.2174/978160805290511201010003

    Google Scholar 

  144. Mocellin S, Pilati P, Lise M et al (2007) Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J Clin Oncol 25:5649–5654

    PubMed  Google Scholar 

  145. Modlin IM et al (2005) Current status of gastrointestinal carcinoids. Gastroenterology 128(6):1717–1751

    PubMed  Google Scholar 

  146. Modlin IM et al (2008) Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 9(1):61–72

    CAS  PubMed  Google Scholar 

  147. Moertel CG et al (1994) The management of Patients with advanced carcinoid tumors and islet cell carcinomas. Ann Intern Med 120(4):302–309

    CAS  PubMed  Google Scholar 

  148. Monna T, Kanno T, Marumo T, Harihara S, Kuroki T, Yamamoto S et al (1982) A comparison of transcatheter arterial embolization with one shot therapy for the Patients with hepatic cell carcinomA. Gastroenterol Jpn 17(6):542–549. Epub 1982/12/01

    CAS  PubMed  Google Scholar 

  149. Müller H, Nakchbandi V, Chatzisavvidis I, von Voigt C (2003) Repetitive chemoembolization with melphalan plus intra-arterial immuno-chemotherapy within 5-fluorouracil and granulocyte-macrophage colony-stimulating factor (GM-CSF) as effective first- and second-line treatment of disseminated colorectal liver metastases. Hepato-Gastroenterology 50:1919–1926

    PubMed  Google Scholar 

  150. Namur J et al (2011) Embolization of hepatocellular carcinoma with drug-eluting beads: doxorubicin tissue concentration and distribution in Patient liver explants. J Hepatol 55(6):1332–1338

    CAS  PubMed  Google Scholar 

  151. Narayanan G, Barbery K, Suthar R et al (2013) Transarterial chemoembolization using DEBIRI for treatment of hepatic metastases from colorectal cancer. Anticancer Res 33:2077–2084

    CAS  PubMed  Google Scholar 

  152. Noter S, Rothbarth J, Pijl MEJ et al (2004) Isolated hepatic perfusion with high-dose melphalan fort he treatment of uveal melanoma metastases confined tot he liver. Melanoma Res 14:67–72

    CAS  PubMed  Google Scholar 

  153. Ogawa M, Takayasu K, Hirayama M, Miura T, Shiozawa K, Abe M et al (2016) Efficacy of a microballoon catheter in transarterial chemoembolization of hepatocellular carcinoma using miriplatin, a lipophilic anticancer drug: short-term results. Hepatol Res 46(3):E60–E69

    CAS  PubMed  Google Scholar 

  154. Ono Y, Yoshimasu T, Ashikaga R, Inoue M, Shindou H, Fuji K et al (2000) Long-term results of lipiodol-transcatheter arterial embolization with cisplatin or doxorubicin for unresectable hepatocellular carcinomA. Am J Clin Oncol Cancer Clin Trials 23(6):564–568

    CAS  Google Scholar 

  155. Pape UF et al (2008) Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours. Endocr Relat Cancer 15(4):1083–1097

    PubMed  Google Scholar 

  156. Paprottka PM et al (2012) Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. Cardiovasc Interv Radiol 35(2):334–342

    Google Scholar 

  157. Park S-Y, Kim JH, Yoo JH et al (2011) Transarterial chemoembolization versus supportive therapy in the palliative treatment of unresectable intrahepatic cholangiocarcinoma. Clin Radiol 66:322–328

    PubMed  Google Scholar 

  158. Pavel M et al (2010) ENETS consensus guidelines for the management of brain, cardiac and ovarian metastases from neuroendocrine tumors. Neuroendocrinology 91(4):326–332

    CAS  PubMed  Google Scholar 

  159. Pavel M et al (2012) ENETS Consensus Guidelines for the management of Patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2):157–176

    CAS  PubMed  Google Scholar 

  160. Pavel M et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103(2):172–185

    CAS  PubMed  Google Scholar 

  161. Peker A et al (2015) Radioembolization with yttrium-90 resin microspheres for neuroendocrine tumor liver metastases. Diagn Interv Radiol 21(1):54–59

    PubMed  Google Scholar 

  162. Perry LJ, Stuart K, Stokes K et al (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Surgery 116:1111–1117

    CAS  PubMed  Google Scholar 

  163. Pingpank JF, Libutti SK, Chang R, Wood BJ, Neeman Z, Kam AW, Figg WD, Zhai S, Beresneva T, Seidel GD, Alexander HR (2005) Phase I study of hepatic arterial melphalan infusion and hepatic venous hemofiltration using percutaneously placed catheters in Patients with unresectable hepatic malignancies. J Clin Oncol 23(15):3465–3474. [PMID: 15908655 PMCID: PMC2374756]. https://doi.org/10.1200/JCO.2005.00.927

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  164. Pitt SC et al (2008) Hepatic neuroendocrine metastases: chemo- or bland embolization? J Gastrointest Surg 12(11):1951–1960

    PubMed  PubMed Central  Google Scholar 

  165. Radeleff BA, Stampfl U, Sommer CM, Bellemann N, Hoffmann K, Ganten T et al (2012) Transarterial ablation of hepatocellular carcinomA. Status and developments. Radiologe 52(1):44–55

    CAS  PubMed  Google Scholar 

  166. Rao PP et al (2012) Irinotecan loaded in eluting beads: preclinical assessment in a rabbit VX2 liver tumor model. Cardiovasc Interv Radiol 35(6):1448–1459

    Google Scholar 

  167. Ridge JA, Bading JR, Gelbard AS, Benua RS, Daly JM (1987) Perfusion of colorectal hepatic metastases. Relative distribution of flow from the hepatic artery and portal vein. Cancer 59(9):1547–1553. [PMID: 3828954]

    CAS  PubMed  Google Scholar 

  168. Rindi G et al (2007) Prognostic factors in gastrointestinal endocrine tumors. Endocr Pathol 18(3):145–149

    PubMed  Google Scholar 

  169. Roche A et al (2003) Trans-catheter arterial chemoembolization as first-line treatment for hepatic metastases from endocrine tumors. Eur Radiol 13(1):136–140

    PubMed  Google Scholar 

  170. Roche A et al (2004) Prognostic factors for chemoembolization in liver metastasis from endocrine tumors. Hepato-Gastroenterology 51(60):1751–1756

    CAS  PubMed  Google Scholar 

  171. Ruszniewski P, Malka D (2000) Hepatic arterial chemoembolization in the management of advanced digestive endocrine tumors. Digestion 62(Suppl 1):79–83

    PubMed  Google Scholar 

  172. Ruszniewski P et al (1993) Hepatic arterial chemoembolization in Patients with liver metastases of endocrine tumors. A prospective phase II study in 24 patients. Cancer 71(8):2624–2630

    Google Scholar 

  173. Ruutiainen AT et al (2007) Chemoembolization and bland embolization of neuroendocrine tumor metastases to the liver. J Vasc Interv Radiol 18(7):847–855

    PubMed  Google Scholar 

  174. Sakamoto I, Aso N, Nagaoki K, Matsuoka Y, Uetani M, Ashizawa K et al (1998) Complications associated with transcatheter arterial embolization for hepatic tumors. Radiographics 18(3):605–619

    CAS  PubMed  Google Scholar 

  175. Sakamoto I et al (2003) Intrahepatic biloma formation (bile duct necrosis) after transcatheter arterial chemoembolization. AJR Am J Roentgenol 181(1):79–87

    PubMed  Google Scholar 

  176. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S, Atassi B, Baker T, Gates V, Miller FH, Sato KT, Wang E, Gupta R, Benson AB, Newman SB, Omary RA, Abecassis M, Kulik L (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report pf long-term outcomes. Gastroenterology 138:52–64

    CAS  PubMed  Google Scholar 

  177. Salman HS, Cynamon J, Jagust M et al (2002) Randomized phase II trial of embolization therapy versus chemoembolization therapy in previously treated patients with colorectal carcinoma metastatic to the liver. Clin Colorectal Cancer 2:173–179

    CAS  PubMed  Google Scholar 

  178. Samaras P, Breitenstein S, Haile SR et al (2011) Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases. Ann Surg Oncol 18:1924–1931

    PubMed  Google Scholar 

  179. Sangro B, Salem R, Kennedy A, Coldwell D, Wasan H (2011a) Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol 34:422–431

    PubMed  Google Scholar 

  180. Sangro B, Carpanese L, Cianni R, Golfieri R, Gasparini D, Ezziddin S, Paprottka PM, Fiore F, Van Buskirk M, Bilbao JI, Ettorre GM, Salvatori R, Giampalma E, Geatti O, Wilhelm K, Hoffmann RT, Izzo F, Iñarrairaegui M, Maini CL, Urigo C, Cappelli A, Vit A, Ahmadzadehfar H, Jakobs TF, Lastoria S (2011b) Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 54:868–878

    PubMed  Google Scholar 

  181. Saxena A, Chua TC, Bester L, Kokandi A, Morris DL (2010a) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251:910–916

    PubMed  Google Scholar 

  182. Saxena A et al (2010b) Factors predicting response and survival after yttrium-90 radioembolization of unresectable neuroendocrine tumor liver metastases: a critical appraisal of 48 cases. Ann Surg 251(5):910–916

    PubMed  Google Scholar 

  183. Saxena A et al (2011) Progression and survival results after radical hepatic metastasectomy of indolent advanced neuroendocrine neoplasms (NENs) supports an aggressive surgical approach. Surgery 149(2):209–220

    PubMed  Google Scholar 

  184. Schalhorn A (2003) Allgemeine und spezielle Phamakologie. In: Boese-Landgraf J, Gallkowski U et al (Hrsg) Regionale Tumortherapie. Springer, Berlin/Heidelberg/New York, S 5–10

    Google Scholar 

  185. Schell SR, Camp ER, Caridi JG et al (2002) Hepatic artery embolization fot control of symptoms, octreotide requirements, and tumor progression in metastatic carcinoid tumors. J Gastrointest Surg 6:664–670

    PubMed  Google Scholar 

  186. Scheuermann U, Kaths JM, Heise M et al (2013) Comparison of resection and transarterial chemoembolization in the treatment of advanced intrahepatic cholangiocracinoma – a single-center experience. Eur J Surg Oncol 39:593–600

    Google Scholar 

  187. Schimmack S et al (2011) The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors. Langenbeck's Arch Surg 396(3):273–298

    Google Scholar 

  188. Seidensticker R, Denecke T, Kraus P, Seidensticker M, Mohnike K, Fahlke J, Kettner E, Hildebrandt B, Dudeck O, Pech M, Amthauer H, Ricke J (2012) Matched-pair comparison of radioembolization plus best supportive care versus best supportive care alone for chemotherapy refractory liver-dominant colorectal metastases. Cardiovasc Interv Radiol 35:1066–1073

    Google Scholar 

  189. Sergio A, Cristofori C, Cardin R, Pivetta G, Ragazzi R, Baldan A et al (2008) Transcatheter arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): the role of angiogenesis and invasiveness. Am J Gastroenterol 103(4):914–921. Epub 2008/01/08

    PubMed  Google Scholar 

  190. Shiba H, Ishida Y, Wakiyama S, Sakamoto T, Misawa T, Yanaga K (2008) Acute tumor lysis syndrome after transarterial chemoembolization for hepatocellular carcinoma. Cancer Sci 99(10):2104–2105

    CAS  PubMed  Google Scholar 

  191. Shitara K, Ikami I, Munakata M et al (2008) Hepatic arterial infusion of Mitomycin C with degradable starch microspheres for unresectable intrahepatic cholangiocarcinoma. Clin Oncol 20:241–246

    CAS  Google Scholar 

  192. Siegal T, Horowitz A, Gabizon A (1995) Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg 83(6):1029–1037. Epub 1995/12/01

    CAS  PubMed  Google Scholar 

  193. Sofocleous CT et al (2014) Factors affecting periprocedural morbidity and mortality and long-term Patient survival after arterial embolization of hepatic neuroendocrine metastases. J Vasc Interv Radiol 25(1):22–30. quiz 31

    Google Scholar 

  194. Sommer CM, Stampfl U, Kauczor HU, Pereira PL (2014) National S3 guidelines on hepatocellular carcinoma. Radiologe 54(7):642–653

    CAS  PubMed  Google Scholar 

  195. Song SY, Chung JW, Han JK, Lim HG, Koh YH, Park JH et al (2001) Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predisposing factors, and clinical outcome. J Vasc Interv Radiol 12(3):313–320. Epub 2001/04/05

    CAS  PubMed  Google Scholar 

  196. Sorbye H et al (2013) Predictive and prognostic factors for treatment and survival in 305 Patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol 24(1):152–160

    CAS  PubMed  Google Scholar 

  197. Stampfl S, Stampfl U, Bellemann N, Sommer CM, Thierjung H, Radeleff B et al (2008) Biocompatibility and recanalization characteristics of hydrogel microspheres with polyzene-F as polymer coating. Cardiovasc Interv Radiol 31(4):799–806. Epub 2008/01/25

    Google Scholar 

  198. Steinmuller T et al (2008) Consensus guidelines for the management of Patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 87(1):47–62

    PubMed  Google Scholar 

  199. Steward MJ et al (2008) Neuroendocrine tumors: role of interventional radiology in therapy. Radiografics 28(4):1131–1145

    Google Scholar 

  200. Stutz M, Mamo A, Valenti D et al (2015) Real-life report on chemoembolization using DEBIRI for liver metastases from colorectal cancer. Gastroenterol Res Pract 715102:1–6

    Google Scholar 

  201. Tajima T, Yoshimitsu K, Kuroiwa T, Ishibashi T, Irie H, Aibe H et al (2005) Percutaneous femoral catheter placement for long-term chemotherapy infusions: preliminary technical results. AJR Am J Roentgenol 184(3):906–914. Epub 2005/02/25

    PubMed  Google Scholar 

  202. Takayasu K, Shima Y, Muramatsu Y, Moriyama N, Yamada T, Makuuchi M et al (1987) Hepatocellular-carcinoma – treatment with intraarterial iodized oil with and without chemotherapeutic-agents. Radiology 163(2):345–351

    Google Scholar 

  203. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T et al (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 Patients. Gastroenterology 131(2):461–469

    Google Scholar 

  204. Tang L (2008) High grade transformation of differentiated neuroendocrine neoplasms (NENs) of the enteropancreatic system – a unique en- tity distinct from de novo high grade neuroendocrine carcinoma (HGNECa) in pathogenesis and clinical behavior. Mod Pathol 21:137A

    Google Scholar 

  205. Telez C, Benson AB III, Lyster MT et al (1998) Phase II trial of chemoembolization for the treatment of metastatic colorectal carcinoma to the liver and review oft he literature. Cancer 82:1250–1259

    Google Scholar 

  206. Therasse E et al (1993) Transcatheter chemoembolization of progressive carcinoid liver metastasis. Radiology 189(2):541–547

    CAS  PubMed  Google Scholar 

  207. Tsimberidou AM, Vaklavas C, Fu S et al (2013) Hepatic arterial infusion therapy in advanced cancer and liver-predominant disease: the MD Anderson experience. Hepato-Gastroenterology 60:1611–1623

    CAS  PubMed  Google Scholar 

  208. Vahrmeijer AL (2014) Liver metastases: a new treatment paradigm. Presented at: 34th Congress of the European Society of Surgical Oncology Liverpool. S 29–31

    Google Scholar 

  209. Vahrmeijer AL, van Dierendonck JH, Keizer HJ, Beijnen JH, Tollenaar RA, Pijl ME, Marinelli A, Kuppen PJ, van Bockel JH, Mulder GJ, van de Velde CJ (2000) Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in Patients with colorectal cancer confined to the liver. Br J Cancer 82(9):1539–1546. [PMID: 10789721 PMCID: PMC2363396]. https://doi.org/10.1054/bjoc.2000.1175

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  210. Van Hazel GA, Blackwell A, Anderson J, Price D, Moroz P, Bower G, Cardaci G, Gray B (2004) Randomnized phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 88:78–85

    Google Scholar 

  211. Van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, Perez D, Robinson BA, Strickland AH, Ferguson T, Rodríguez J, Kröning H, Wolf I, Ganju V, Walpole E, Boucher E, Tichler T, Shacham-Shmueli E, Powell A, Eliadis P, Isaacs R, Price D, Moeslein F, Taieb J, Bower G, Gebski V, Van Buskirk M, Cade DN, Thurston K, Gibbs P (2016) SIRFLOX: randomized phase III trial comparing first-line mFOLFOX6 (plus or minus bevacizumab) versus mFOLFOX6 (plus or minus bevacizumab) plus selective internal radiation therapy in patients with metastatic colorectal cancer. J Clin Oncol 20;34(15):1723–1731. https://doi.org/10.1200/JCO.2015.66.1181. Epub 2016 Feb 22

  212. Van Iersel LB, Gelderblom H, Vahrmeijer AL, van Persijn van Meerten EL, Tijl FG, Putter H, Hartgrink HH, Kuppen PJ, Nortier JW, Tollenaar RA, van de Velde CJ (2008) Isolated hepatic melphalan perfusion of colorectal liver metastases: outcome and prognostic factors in 154 patients. Ann Oncol 19(6):1127–1134 [PMID: 18304962] https://doi.org/10.1093/annonc/mdn032

  213. Van Iersel LB, de Leede EM, Vahrmeijer AL, Tijl FG, den Hartigh J, Kuppen PJ, Hartgrink HH, Gelderblom H, Nortier JW, Tollenaar RA, van de Velde CJ (2014) Isolated hepatic perfusion with oxaliplatin combined with 100 mg melphalan in patients with metastases confined to the liver: a phase I study. Eur J Surg Oncol 40(11):1557–1563. [PMID: 25125340]. https://doi.org/10.1016/j.ejso.2014.06.010

    Article  PubMed  Google Scholar 

  214. Van Loon K et al (2015) Bone metastases and skeletal-related events from neuroendocrine tumors. Endocr Connect 4(1):9–17

    PubMed  PubMed Central  Google Scholar 

  215. Venturini M, Angeli E, Salvioni M, De Cobelli F, Ronzoni M, Aldrighetti L et al (2004) Complications after percutaneous transaxillary implantation of a catheter for intraarterial chemotherapy of liver tumors: clinical relevance and management in 204 Patients. AJR Am J Roentgenol 182(6):1417–1426. Epub 2004/05/20

    Google Scholar 

  216. Vogel A, Gupta S, Zeile M, von Haken R, Bruning R, Lotz G, Vahrmeijer A, Vogl T, Wacker F (2017) Chemosaturation percutaneous hepatic perfusion: a systematic review. Adv Ther 33(12):2122–2138. [PMID: 27798773 PMCID: PMC5126197]. https://doi.org/10.1007/s12325-016-0424-4

    Article  CAS  PubMed  Google Scholar 

  217. Vogl T, Naguib NNN, Nour-Eldin A et al (2012) Transarterial chemoembolization in the treatment of Patients with unresectable cholangiocarcinoma: results and prognostic factors governing treatment success. Int J Cancer 131:733–740

    CAS  PubMed  Google Scholar 

  218. Vogl TJ, Zangos S, Balzer JO, Nabil M, Rao P, Eichler K et al (2007) Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results]. Roefo 179(11):1113–1126. Epub 2007/10/20. Transarterielle Chemoembolisation (TACE) des hepatozellularen Karzinoms: Technik, Indikationsstellung und Ergebnisse

    CAS  Google Scholar 

  219. Vogl TJ, Zangos S, Scholtz JE, Schmitt F, Paetzold S, Trojan J, Orsi F, Lotz G, Ferrucci P (2014) Chemosaturation with percutaneous hepatic perfusions of melphalan for hepatic metastases: experience from two European centers. Röfo 186(10):937–944. [PMID: 24729409]. https://doi.org/10.1055/s-0034-1366081

    Article  CAS  PubMed  Google Scholar 

  220. Wang K, Chen Z (2010) Acute tumor lysis syndrome after transarterial chemoembolization for well-differentiated hepatocellular carcinoma with neuroendocrine features. Onkologie 33(10):532–535

    CAS  PubMed  Google Scholar 

  221. Watanabe S, Nishioka M, Ohta Y, Ogawa N, Ito S, Yamamoto Y (1994) Prospective and randomized controlled-study of chemoembolization therapy in patients with advanced hepatocellular-carcinoma. Cancer Chemother Pharmacol 33:S93–S96

    PubMed  Google Scholar 

  222. Woo S, Chung JW, Hur S, Joo SM, Kim HC, Jae HJ et al (2013) Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol 200(6):1370–1377

    PubMed  Google Scholar 

  223. Woo S, Kim H-C, Chung JW et al (2015) Chemoembolization of extrahepatic collateral arteries for treatment of hepatocellular carcinoma in the caudate lobe of the liver. Cardiovasc Interv Radiol 38:389–396

    Google Scholar 

  224. Wu XZ, Xie GR, Chen D (2007) Hypoxia and hepatocellular carcinoma: the therapeutic target for hepatocellular carcinomA. J Gastroenterol Hepatol 22(8):1178–1182. Epub 2007/06/15

    CAS  PubMed  Google Scholar 

  225. Yao JC et al (2008) One hundred years after „carcinoid“: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26(18):3063–3072

    PubMed  Google Scholar 

  226. Yu JS et al (2001) Bile duct injuries leading to portal vein obliteration after transcatheter arterial chemoembolization in the liver: CT findings and initial observations. Radiology 221(2):429–436

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Max Grundig Klinik GmbH, Bühl, Deutschland

    Peter Huppert

  2. Institut für Radiologie, Neuroradiologie und Nuklearmedizin Städtisches Klinikum Darmstadt, Darmstadt, Deutschland

    Nikolas Kortes

  3. Abteilung Nuklearmedizin, Universitätsklinikum Heidelberg, Heidelberg, Deutschland

    Clemens Kratochwil

  4. Abteilung Diagnostische und Interventionelle Radiologie, Sana Klinikum Hof GmbH, Hof, Deutschland

    Boris Radeleff

  5. Ludwigshafen Klinikum d. Stadt Ludwigshafen Zentralinstitut für Diagnostische und Interventionelle Radiologie, Ludwigshafen, Deutschland

    Anne Schmitz

  6. Diagnostikzentrum Esslingen, Esslingen am Neckar, Deutschland

    Ulrike Stampfl

Authors
  1. Peter Huppert
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nikolas Kortes
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clemens Kratochwil
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Boris Radeleff
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne Schmitz
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulrike Stampfl
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Huppert .

Editor information

Editors and Affiliations

  1. Diagnostische und Intervent. Radiologie, Sana Klinikum Hof GmbH Diagnostische und Intervent. Radiologie, Hof/Saale, Germany

    Boris Radeleff

Rights and permissions

Reprints and permissions

Copyright information

© 2021 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Huppert, P., Kortes, N., Kratochwil, C., Radeleff, B., Schmitz, A., Stampfl, U. (2021). Onkologische Embolisation. In: Radeleff, B. (eds) Angiofibel. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-56243-7_14

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-56243-7_14

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-56242-0

  • Online ISBN: 978-3-662-56243-7

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation